Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alfacell’s president and CFO resigns
Mr Kenyon has accepted a full time position as executive vice president of finance at Par Pharmaceutical, effective December 15, 2008. In addition, the company has also announced
Mr Kenyon has accepted a full time position as executive vice president of finance at Par Pharmaceutical, effective December 15, 2008. In addition, the company has also announced
Under the agreement, Access MediQuip will provide device benefit management services to WellPoint members, including insurance authorization, logistics management, and claims processing for orthopedic, spinal, pain management and
The multi-year distribution agreement began on November 1, 2008 and includes HealthTrust Purchasing Group’s (HPG’s) acute care and alternate site locations. By being awarded a contract for medical
Mr Kay will join Algeta from Renovo, where he was executive director of commercial operations. He brings more than 25 years of commercial experience in the pharmaceutical sector.
In connection with the completion of the acquisition, Affymetrix is paying approximately $73 million in cash to acquire Panomics.Founded in 2000, Panomics offers a platform of reagents and
According to the company, Eurartesim, a Phase III product candidate, aims to treat uncomplicated Plasmodium falciparum malaria in adults and children, while reducing the potential for re-infection. The
The marketing authorization is supported by data from two international, double-blind, randomized, placebo-controlled Phase III clinical trials in patients with hyperphenylalaninemia (HPA) due to phenylketonuria (PKU). According to
According to the company, both the lumican monoclonal antibody and the keratocan monoclonal antibody are IgM antibodies that are affinity purified on a thiophilic column. The lumican antibody
HemaQuest performed two different trials. In the first placebo-controlled clinical study, 32 healthy volunteers were given single doses of HQK-1001, ranging from two to 20mg/kg. This trial was
The Phase I trial is an open label study being conducted at Erasmus University Medical Center, Rotterdam, The Netherlands under the direction of M de Jonge. The objectives